Table 2

Change from baseline to week 16 in efficacy endpoints

Filgotinib
200 mg (n=4)
Lanraplenib
30 mg (n=1)
24-hour urine protein in g/day, median change (% change)−1.4 (−50.7)−0.2 (−2.8)
Spot UPCR in mg/mg, median change (% change)−0.4 (−51.6)−2.2 (−30.7)
24-hour UPCR in mg/mg, median change (% change)−0.7 (−45.5)−4.4 (−52.0)
eGFR in mL/min/1.73 m2, median change−1.2−59.4
Partial remission, n (%)2 (50.0)0 (0.0)
Complete remission, n (%)0 (0.0)0 (0.0)
SELENA-SLEDAI total score, median change (% change)0.0 (0.0)4.0 (50.0)
Physician global assessment score, median % change−71.414.0
Patient global assessment score, median % change−50.8−33.3
Anti-dsDNA in IU/mL, median change11.00.0
C3 complement component in mg/dL, median change−19.3−17.7
C4 complement component in mg/dL, median change−2.5−3.2
  • anti-dsDNA, anti-double-stranded DNA antibody; eGFR, estimated glomerular filtration rate; SELENA-SLEDAI, Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; UPCR, urine protein to creatinine ratio.